Nexavar (sorafenib tosylate) — United Healthcare
thyroid cancer
Preferred products
- Caprelsa (vandetanib)
- Cometriq (cabozantinib)
Initial criteria
- Option 1:
- Diagnosis of follicular carcinoma OR oncocytic carcinoma OR papillary carcinoma
- AND Unresectable recurrent disease OR Persistent locoregional disease OR Metastatic disease
- AND Patient has symptomatic disease OR progressive disease
- AND Disease is refractory to radioactive iodine treatment
- OR Option 2:
- Diagnosis of medullary thyroid carcinoma
- AND Disease is progressive OR symptomatic with distant metastases
- AND History of failure, contraindication, or intolerance to Caprelsa (vandetanib) OR Cometriq (cabozantinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Nexavar therapy
Approval duration
12 months